Brain insulin resistance (diabetes) is very much like regular diabetes. We believe that the development of new therapies would be applicable for all types of diabetes, including Alzheimer's disease, which we refer to as Type III diabetes.
+Alzheimer's Reading Room
The research found that once AD is established, therapeutic efforts must also work to reduce toxin production in the brain.
The study, Dysfunctional Pro-Ceramide, ER Stress, and Insulin/IGF Signaling Networks with Progression of Alzheimer's Disease, is published in the supplement of the Journal of Alzheimer's Disease.
|Subscribe to the Alzheimer's Reading Room|
Link between brain insulin resistance, neuronal stress in worsening Alzheimer's disease
Rhode Island Hospital study takes next step in breaking brain's cycle of creating toxins that cause Alzheimer's to progress
Alzheimer's disease is one of the most common degenerative dementias, and more than 115 million new cases are projected worldwide in the next 40 years.
There is clinical and experimental evidence that treatment with insulin or insulin sensitizer agents can enhance cognitive function and in some circumstances help slow the rate of cognitive decline in AD.
Alzheimer's and other neurodegenerative diseases destroy the brain until the patients finally succumb.
In order to effectively halt the process of neurodegeneration, the forces that advance and perpetuate the disease, particularly with regard to the progressive worsening of brain insulin/IGF resistance, must be understood.
"Brain insulin resistance (diabetes) is very much like regular diabetes," de la Monte said. "Since the underlying problems continue to be just about the same, we believe that the development of new therapies would be applicable for all types of diabetes, including Alzheimer's disease, which we refer to as Type III diabetes."
She continued, "This study points out that once AD is established, therapeutic efforts should target several different pathways—not just one. The reason is that a positive feedback loop gets going, making AD progress. We have to break the vicious cycle. Restoring insulin responsiveness and insulin depletion will help, but we need to reduce brain stress and repair the metabolic problems that cause the brain to produce toxins."Ultimately, these findings will help to expand ways to both detect and treat AD.
Growing evidence supports the concept that AD is fundamentally a metabolic syndrome that leads to abnormalities linked to brain insulin and insulin-like growth factor (IGF) resistance.
In AD, brain insulin and IGF resistance and deficiencies begin early and worsen with severity of the disease. The rationale behind the progression of the disease is that insulin-resistance dysregulates lipid metabolism and promotes ceramide accumulation, thereby increasing inflammation and lipid metabolism, causing toxic ceramides to accumulate in the brain. The end result is increased stress that threatens the survival and function of neurons in the brain.
The present study was designed to gain a better understanding of how brain insulin resistance becomes progressive and contributes to the neurodegeneration in AD, focusing on the roles of ceramides and stress. The researchers studied the same brain samples used previously to demonstrate progressive impairments in brain insulin/IGF signaling with increasing severity of AD.
The National Institutes of Health funded the study (grant #R01 AA11431, AA12908, AA16126). De la Monte's principal affiliation is Rhode Island Hospital, a member hospital of the Lifespan health system in Rhode Island. She also has an academic appointment at The Warren Alpert Medical School of Brown University. Their research is fully supported by Rhode Island Hospital and the Lifespan health system.
About Rhode Island Hospital
Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of The Warren Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research.
Original content Bob DeMarco, the Alzheimer's Reading Room